$XERS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in XERIS PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in XERIS PHARMACEUTICALS INC. Get notifications about new insider transactions in XERIS PHARMACEUTICALS INC for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 08 2021 | XERS | XERIS PHARMACEUTIC ... | BORMANN-KENNEDY BARBARA-JEAN A ... | Director | Option Exercise | A | 3.90 | 11,228 | 43,789 | 11,228 | |
| Apr 13 2021 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 4.07 | 10,000 | 40,725 | 496,824 | 506.8 K to 496.8 K (-1.97 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | A | 5.08 | 400,000 | 2,032,000 | 400,000 | |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 225,000 | 0 | 636,134 | 411.1 K to 636.1 K (+54.73 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 0.00 | 150,000 | 0 | 271,224 | 121.2 K to 271.2 K (+123.74 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Grant | A | 0.00 | 100,000 | 0 | 506,824 | 406.8 K to 506.8 K (+24.58 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Grant | A | 0.00 | 65,000 | 0 | 91,890 | 26.9 K to 91.9 K (+241.73 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 0.00 | 150,000 | 0 | 210,814 | 60.8 K to 210.8 K (+246.65 %) |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Grant | A | 0.00 | 115,000 | 0 | 208,090 | 93.1 K to 208.1 K (+123.54 %) |
| Jan 15 2021 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 6.01 | 10,000 | 60,058 | 406,824 | 416.8 K to 406.8 K (-2.40 %) |
| Jan 12 2021 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 5.72 | 10,000 | 57,244 | 416,824 | 426.8 K to 416.8 K (-2.34 %) |
| Dec 17 2020 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Gift | G | 0.00 | 10,000 | 0 | 426,824 | 436.8 K to 426.8 K (-2.29 %) |
| Dec 10 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.06 | 10,000 | 40,551 | 411,134 | 401.1 K to 411.1 K (+2.49 %) |
| Dec 10 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.06 | 10,000 | 40,551 | 411,134 | 401.1 K to 411.1 K (+2.49 %) |
| Aug 20 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Option Exercise | A | 4.29 | 100,000 | 429,000 | 100,000 | |
| Aug 17 2020 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Option Exercise | A | 4.19 | 100,000 | 419,000 | 100,000 | |
| Aug 17 2020 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | A | 4.19 | 25,000 | 104,750 | 25,000 | |
| Aug 17 2020 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Option Exercise | A | 4.19 | 100,000 | 419,000 | 100,000 | |
| Jul 15 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 2.26 | 3,731 | 8,432 | 60,814 | 57.1 K to 60.8 K (+6.54 %) |
| Jul 15 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 2.26 | 3,731 | 8,432 | 121,224 | 117.5 K to 121.2 K (+3.18 %) |
| Jul 15 2020 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Grant | A | 2.26 | 3,731 | 8,432 | 93,090 | 89.4 K to 93.1 K (+4.18 %) |
| Jul 15 2020 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Grant | A | 2.26 | 775 | 1,752 | 26,890 | 26.1 K to 26.9 K (+2.97 %) |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | PERSKY MARLA | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | Schmid John P. | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | Thierer Mark | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | HALKUFF DAWN | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | BORMANN-KENNEDY BARBARA-JEAN A ... | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| Jun 04 2020 | XERS | XERIS PHARMACEUTIC ... | SHERMAN JEFFREY W | Director | Option Exercise | A | 4.68 | 11,228 | 52,547 | 11,228 | |
| May 11 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Buy | P | 3.20 | 7,886 | 25,219 | 95,493 | 87.6 K to 95.5 K (+9.00 %) |
| May 11 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 3.00 | 33,000 | 99,000 | 401,134 | 368.1 K to 401.1 K (+8.96 %) |
| Mar 16 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Buy | P | 1.97 | 4,000 | 7,880 | 57,083 | 53.1 K to 57.1 K (+7.54 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Grant | A | 0.00 | 15,000 | 0 | 436,824 | 421.8 K to 436.8 K (+3.56 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Grant | A | 0.00 | 20,000 | 0 | 26,115 | 6.1 K to 26.1 K (+327.06 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 0.00 | 45,000 | 0 | 53,083 | 8.1 K to 53.1 K (+556.72 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 0.00 | 45,000 | 0 | 53,083 | 8.1 K to 53.1 K (+556.72 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 0.00 | 65,000 | 0 | 87,607 | 22.6 K to 87.6 K (+287.52 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 0.00 | 65,000 | 0 | 87,607 | 22.6 K to 87.6 K (+287.52 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 185,000 | 0 | 368,134 | 183.1 K to 368.1 K (+101.02 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 185,000 | 0 | 368,134 | 183.1 K to 368.1 K (+101.02 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Grant | A | 0.00 | 50,000 | 0 | 89,359 | 39.4 K to 89.4 K (+127.04 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Grant | A | 0.00 | 50,000 | 0 | 89,359 | 39.4 K to 89.4 K (+127.04 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Buy | P | 4.15 | 12,048 | 49,999 | 22,607 | 10.6 K to 22.6 K (+114.10 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Buy | P | 4.15 | 4,000 | 16,600 | 8,083 | 4.1 K to 8.1 K (+97.97 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.15 | 20,000 | 83,000 | 183,134 | 163.1 K to 183.1 K (+12.26 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Buy | P | 4.15 | 2,410 | 10,002 | 6,115 | 3.7 K to 6.1 K (+65.05 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Buy | P | 4.15 | 9,639 | 40,002 | 39,359 | 29.7 K to 39.4 K (+32.43 %) |
| Feb 04 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Payment of Exercise | F | 6.37 | 9,801 | 62,432 | 163,134 | 172.9 K to 163.1 K (-5.67 %) |
| Jan 14 2020 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 5.50 | 10,000 | 54,992 | 421,824 | 431.8 K to 421.8 K (-2.32 %) |
| Jan 14 2020 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 5.50 | 10,000 | 54,992 | 421,824 | 431.8 K to 421.8 K (-2.32 %) |
| Jan 06 2020 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 5.99 | 459 | 2,749 | 4,083 | 3.6 K to 4.1 K (+12.67 %) |
| Jan 06 2020 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Grant | A | 5.99 | 286 | 1,713 | 3,705 | 3.4 K to 3.7 K (+8.37 %) |
| Jan 06 2020 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 5.99 | 438 | 2,624 | 10,559 | 10.1 K to 10.6 K (+4.33 %) |
| Nov 27 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 8.55 | 17,935 | 153,283 | 172,935 | 155 K to 172.9 K (+11.57 %) |
| Nov 27 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 8.55 | 17,935 | 153,283 | 172,935 | 155 K to 172.9 K (+11.57 %) |
| Nov 20 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Gift | G | 0.00 | 17,500 | 0 | 431,824 | 449.3 K to 431.8 K (-3.89 %) |
| Oct 16 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 7.97 | 10,000 | 79,746 | 449,324 | 459.3 K to 449.3 K (-2.18 %) |
| Oct 16 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 12.70 | 38 | 483 | 459,324 | 459.4 K to 459.3 K (-0.01 %) |
| Oct 16 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 12.04 | 9,962 | 119,913 | 459,362 | 469.3 K to 459.4 K (-2.12 %) |
| Oct 16 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 17.20 | 7,700 | 132,459 | 469,324 | 477 K to 469.3 K (-1.61 %) |
| Oct 02 2019 | XERS | XERIS PHARMACEUTIC ... | Thierer Mark | Director | Option Exercise | A | 9.83 | 19,650 | 193,160 | 19,650 | |
| Jul 03 2019 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Grant | A | 9.72 | 1,124 | 10,925 | 3,928 | 2.8 K to 3.9 K (+40.09 %) |
| Jul 03 2019 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Grant | A | 9.72 | 174 | 1,691 | 3,419 | 3.2 K to 3.4 K (+5.36 %) |
| Jul 03 2019 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Grant | A | 9.72 | 1,428 | 13,880 | 29,720 | 28.3 K to 29.7 K (+5.05 %) |
| Jul 03 2019 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Grant | A | 9.72 | 1,138 | 11,061 | 10,121 | 9 K to 10.1 K (+12.67 %) |
| Apr 12 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 9.56 | 10,000 | 95,649 | 477,024 | 487 K to 477 K (-2.05 %) |
| Mar 12 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 9.12 | 30,000 | 273,585 | 155,000 | 125 K to 155 K (+24.00 %) |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | Schmid John P. | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | Schmid John P. | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | HALKUFF DAWN | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | HALKUFF DAWN | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | BORMANN-KENNEDY BARBARA-JEAN A ... | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | BORMANN-KENNEDY BARBARA-JEAN A ... | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | SHERMAN JEFFREY W | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | SHERMAN JEFFREY W | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | PERSKY MARLA | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | PERSKY MARLA | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Mar 01 2019 | XERS | XERIS PHARMACEUTIC ... | RIGBY JONATHAN | Director | Option Exercise | A | 10.00 | 20,000 | 200,000 | 20,000 | |
| Feb 25 2019 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Buy | P | 10.00 | 1,000 | 10,000 | 3,245 | 2.2 K to 3.2 K (+44.54 %) |
| Feb 22 2019 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Buy | P | 10.00 | 5,000 | 50,000 | 28,292 | 23.3 K to 28.3 K (+21.47 %) |
| Feb 22 2019 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Buy | P | 10.00 | 2,500 | 25,000 | 2,500 | 0 to 2.5 K |
| Feb 21 2019 | XERS | XERIS PHARMACEUTIC ... | Redmile Group, LLC | 10% Owner | Buy | P | 10.00 | 588,000 | 5,880,000 | 3,000,642 | 2.4 M to 3 M (+24.37 %) |
| Feb 12 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 1,351 | 20,265 | 856,470 | 857.8 K to 856.5 K (-0.16 %) |
| Feb 12 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.11 | 5,890 | 88,986 | 857,821 | 863.7 K to 857.8 K (-0.68 %) |
| Feb 07 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 9,409 | 141,135 | 863,711 | 873.1 K to 863.7 K (-1.08 %) |
| Feb 07 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 400 | 6,000 | 873,120 | 873.5 K to 873.1 K (-0.05 %) |
| Feb 07 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.07 | 4,998 | 75,308 | 873,520 | 878.5 K to 873.5 K (-0.57 %) |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | See Remarks | Option Exercise | A | 13.88 | 25,000 | 347,000 | 25,000 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | See Remarks | Option Exercise | A | 13.88 | 25,000 | 347,000 | 25,000 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | A | 13.88 | 200,000 | 2,776,000 | 200,000 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Option Exercise | A | 13.88 | 32,500 | 451,100 | 32,500 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Option Exercise | A | 13.88 | 80,000 | 1,110,400 | 80,000 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Hecht Beth | See Remarks | Option Exercise | A | 13.88 | 32,500 | 451,100 | 32,500 | |
| Jan 30 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.14 | 6,210 | 94,028 | 878,518 | 884.7 K to 878.5 K (-0.70 %) |
| Jan 30 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.00 | 828 | 12,420 | 884,728 | 885.6 K to 884.7 K (-0.09 %) |
| Jan 25 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.08 | 76,820 | 1,158,254 | 885,556 | 962.4 K to 885.6 K (-7.98 %) |
| Jan 25 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 15.03 | 5,425 | 81,563 | 962,376 | 967.8 K to 962.4 K (-0.56 %) |
| Jan 25 2019 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 16.35 | 32,199 | 526,376 | 967,801 | 1000 K to 967.8 K (-3.22 %) |
| Jan 15 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 0.00 | 2,300 | 0 | 487,024 | 489.3 K to 487 K (-0.47 %) |
| Jan 02 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | M | 1.19 | 15,720 | 18,707 | 0 | |
| Jan 02 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Sell | S | 15.82 | 15,720 | 248,738 | 489,324 | 505 K to 489.3 K (-3.11 %) |
| Jan 02 2019 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Buy | M | 1.19 | 15,720 | 18,707 | 505,044 | 489.3 K to 505 K (+3.21 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Option Exercise | C | 0.00 | 4,000 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | JOHNSON KENNETH ERLAND | See Remarks | Buy | C | 0.00 | 2,245 | 0 | 2,245 | 0 to 2.2 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | C | 0.00 | 23,922 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | C | 0.00 | 23,922 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | C | 0.00 | 13,430 | 0 | 13,430 | 0 to 13.4 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | C | 0.00 | 13,430 | 0 | 13,430 | 0 to 13.4 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | Chief Financial Off ... | Option Exercise | C | 0.00 | 3,987 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | Chief Financial Off ... | Option Exercise | C | 0.00 | 3,987 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | Chief Financial Off ... | Buy | C | 0.00 | 2,238 | 0 | 23,292 | 21.1 K to 23.3 K (+10.63 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Deutsch Barry M. | Chief Financial Off ... | Buy | C | 0.00 | 2,238 | 0 | 23,292 | 21.1 K to 23.3 K (+10.63 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Option Exercise | C | 0.00 | 16,000 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Option Exercise | C | 0.00 | 16,000 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Buy | C | 0.00 | 8,983 | 0 | 8,983 | 0 to 9 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Shannon John Patrick Jr | See Remarks | Buy | C | 0.00 | 8,983 | 0 | 8,983 | 0 to 9 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | C | 0.00 | 12,701 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | C | 0.00 | 12,701 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | C | 0.00 | 53,849 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Option Exercise | C | 0.00 | 53,849 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Buy | C | 0.00 | 7,130 | 0 | 489,323 | 482.2 K to 489.3 K (+1.48 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Buy | C | 0.00 | 7,130 | 0 | 489,323 | 482.2 K to 489.3 K (+1.48 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Buy | C | 0.00 | 30,232 | 0 | 482,193 | 452 K to 482.2 K (+6.69 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | PRESTRELSKI STEVEN | Chief Scientific Of ... | Buy | C | 0.00 | 30,232 | 0 | 482,193 | 452 K to 482.2 K (+6.69 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,557,292 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 1,557,292 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 624,333 | 9,364,995 | 1,498,666 | 874.3 K to 1.5 M (+71.41 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 125,667 | 1,885,005 | 1,000,000 | 874.3 K to 1000 K (+14.37 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 874,333 | 0 | 874,333 | 0 to 874.3 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 874,333 | 0 | 874,333 | 0 to 874.3 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Redmile Group, LLC | Option Exercise | C | 0.00 | 3,109,796 | 0 | 0 | ||
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Redmile Group, LLC | Buy | P | 15.00 | 666,668 | 10,000,020 | 2,412,642 | 1.7 M to 2.4 M (+38.18 %) | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Redmile Group, LLC | Buy | C | 0.00 | 1,745,974 | 0 | 1,745,974 | 0 to 1.7 M | |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Option Exercise | C | 0.00 | 797,384 | 0 | 0 | |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Option Exercise | C | 0.00 | 1,036,599 | 0 | 0 | |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Option Exercise | C | 0.00 | 1,657,125 | 0 | 0 | |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Buy | P | 15.00 | 150,000 | 2,250,000 | 2,110,061 | 2 M to 2.1 M (+7.65 %) |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Buy | C | 0.00 | 447,686 | 0 | 1,960,061 | 1.5 M to 2 M (+29.60 %) |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Buy | C | 0.00 | 581,992 | 0 | 1,512,375 | 930.4 K to 1.5 M (+62.55 %) |
| Jun 25 2018 | XERS | XERIS PHARMACEUTIC ... | Palmetto Partners, Ltd. | 10% Owner | Buy | C | 0.00 | 930,383 | 0 | 930,383 | 0 to 930.4 K |
Page: 1